Boston Scientific heads into its April 30 Q2 guidance call with the Street still firmly in the bull camp — but with a month of price weakness and a wave of target cuts fresh in the market's memory.
The stock closed at $58.45 on April 28, down 2.5% on the day and off 15.5% from a month ago. That decline follows a Q1 earnings beat on April 22 that initially drove the stock 10.4% higher in a single session — a sharp bounce that nevertheless left BSX well below its pre-tariff highs. The tension heading into this week is simple: the fundamentals impressed, but the macro backdrop and sector valuation reset have squeezed the price anyway.
Analyst reaction to the Q1 print tells most of the story. The direction of travel was unmistakably downward on price targets — but no one cut the rating. Goldman Sachs trimmed its target from $87 to $84 while holding Buy. RBC Capital moved from $105 to $100 on Outperform. Barclays cut from $100 to $96, also Outperform. Wells Fargo's adjustment was more aggressive, slashing from $94 to $75 while keeping Overweight. Canaccord Genuity went furthest, taking its target from $109 all the way to $71 — but still maintained Buy. Across the board, the message from over ten firms updating on April 23 was identical: we believe in the story, we're just marking down to reflect a more uncertain valuation environment. The consensus mean price target now stands at $85.19, still implying roughly 46% upside from the April 28 close — a gap that speaks more to how far the stock has fallen than to any sudden re-rating of the business.
The bull case rests squarely on BSX's exposure to the atrial fibrillation ablation market. Analysts point to post-trial survey data showing procedure volume expectations running around 18% higher, and a global AFib market that could expand from $9 billion to $15 billion by 2028. Bears are less convinced the growth will materialise cleanly — RF and cryo ablation share losses are projected to continue through 2030, operating leverage has been slower to show up than promised, and debt levels are elevated. For now, the Street is betting on the procedure growth story, even with targets cut.
Positioning in the lending market is low-key. Short interest has risen about 11.7% over the past week to 1.74% of the float — still a modest level that falls well short of anything crowded. Borrow is cheap at 0.33% annualised, and availability remains ample, meaning there is no meaningful squeeze dynamic in play. The options market tells a similar story. The put/call ratio eased to 0.52 on April 28, down from readings above 0.62 for most of the prior week. That's modestly above the 20-day mean of 0.45 but far from a defensive extreme — the z-score is under 0.6, and the 52-week high for the ratio is 1.10. In short, neither the lending market nor the options flow is signalling unusual fear or positioning pressure.
Factor scores add some texture. The EPS surprise rank at the 77th percentile confirms the company's consistent track record of beating estimates — relevant context given the Q1 print. EPS momentum over the past 30 days is softer, ranking in the 21st percentile, reflecting the estimate cuts that followed the target reductions. The ORTEX short score of 29.5 has been essentially flat for the past two weeks, consistent with a stock that shorts have noticed but have not yet conviction-built against.
The next data point worth watching is the April 30 call — specifically whether management provides any incremental colour on procedure volume trends and tariff exposure in the device supply chain, which is the variable most likely to move targets further in either direction.
See the live data behind this article on ORTEX.
Open BSX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
